

To the Honourable

Mr Demetrios Lintzeris, President of EOF

Mrs Maria Skouroliakou, 1st vice President of EOF

Mr Nikolaos Choulis, President of the Committee for the Preparation of the List of Prescribed Medicinal Products

Cc.: Mr Adonis Georgiadis, Minister of Health
Mr Antonis Bezas, Deputy Minister of Health
Mrs Christina Papanikolaou, General Secretary of Public Health
Mr Demetrios Kontos, President of EOPYY

Chalandri, October 21, 2013

Subject: Reimbursement and compensation of the cost of the new original medicinal products that were priced on 6/8/2013

Dear ladies and gentlemen,

Further to our letter dated 11/10/2013 (attached hereto), we would like to readdress the **critical issue of the need to immediately include in the Positive List and compensation of cost of the new original medicinal products that were priced with the Prices Bulletin dated August 6, 2013**, for the purposes of protecting the Public Health.

More specifically, although in accordance with the existing legislation, the deadline for the inclusion of the medicinal products in the list ended on September 6, the committee for the preparation of the list of prescribed medicinal products (Positive List) has not yet convened and relevantly decide.

At this point, it is worth pointing out that the said medicinal products were priced in our country with a 2.5 years delay. Moreover, it is reminded that the said medicinal products that concern severe and rare diseases, have already been evaluated on one hand by the Committee for the Evaluation of Innovative Medicinal Products of the Ministry of Health but also by the competent international agencies (EMA, FDA) as innovative, which are priced and compensated with accelerated procedure

Based on the above, the prompt compensation of the cost of the said medicinal products is necessary, in order for Greek patients to gain access to them, especially when some of these medicinal products reduce the expenditure and in any case, with the applicable clawback mechanism the target set for the expenditure of 2013 will on no way be transgressed.

Consequently, we kindly request that you immediately proceed with all necessary actions in order for the existing legislation to apply, i.e.:

- From the medicinal products priced, the ones belonging to the list of severe medical conditions and high cost (Law 3816) must be categorised)
- The medicinal products be included in the Positive List, based on the existing legislation
- Their cost be compensated by EOPYY, based on the existing legislation.

Yours sincerely,

Konstantinos M. Frouzis
President

Paschalis Apostolidis
Vice President